› ›
Publikationen

Publikationen

Im Folgenden finden Sie eine Übersicht über die wichtigsten Publikationen (NEJM, Lancet, Nature, Science, Cell, Nature Genetics, J Clin Oncol, etc.) mit Autor*innen des CIO Bonn. Die Übersicht beschränkt sich auf Veröffentlichungen, in denen CIO-Autor*innen zuerst oder zuletzt genannt sind.

Zeitraum: 2009 bis 2020

 

2020

  1. WHO Classification of Tumours of the Central Nervous System. im Jahr 2000 (3rd edition), 2007 (4th edition), 2016 (revised 4th ed.), 2020/2021 (5th edition) (von Bonn beteiligt: Herr Prof. Pietsch)
  2. WHO Classification of Pediatric Tumours. 2020/2021. (von Bonn beteiligt: Herr Prof. Pietsch)
  3. CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8 + T Cells. Braun M, Roman Aguilera A, Sundarrajan A, Corvino D, Stannard K, Krumeich S,  Das I, Lima L, Meza Guzman L,  Li K, Li R, Salim N, Villancanas Jorge M, Ham S, Kelly G, Vari F, Lepletier A, Raghavendra A, Pearson S, Madore J, Jacquelin S, Effern M, Quine B,  Koufariotis L, Casey M, Nakamura K, Seo E, Hölzel M, Geyer M, Kristiansen G, Taheri T, Ahern E, Hughes B, Wilmott J, Long G, Scolyer R, Batstone M, Landsberg J, Dietrich D, Pop O, Flatz L, Dougall W, Veillette A, Nicholson S, Möller A, Johnston R, Martinet L, Smyth M, Bald T. Immunity. 2020 Oct 13;53(4):805-823.e15. doi: 10.1016/j.immuni.2020.09.010.
  4. Adoptive T Cell Therapy Targeting Different Gene Products Reveals Diverse and Context-Dependent Immune Evasion in Melanoma. Effern M, Glodde N, Braun M, Liebing J, Boll HN, Yong M, Bawden E, Hinze D, van den Boorn-Konijnenberg D, Daoud M, Aymans P, Landsberg J, Smyth MJ, Flatz L, Tüting T, Bald T, Gebhardt T, Hölzel M.Effern M, et al. Among authors: holzel m. 2020 Sep 15;53(3):564-580.e9. doi: 10.1016/j.immuni.2020.07.007. Epub 2020 Aug 3.
  5. PD-1, CTLA4, PD-L1 and PD-L2 DNA methylation in papillary thyroid carcinoma. Vos L, Dietrich J, Strieth S, Bootz F, Dietrich D, Franzen A.Vos L, et al. Among authors: Dietrich D. Immunotherapy. 2020 Aug;12(12):903-920. doi: 10.2217/imt-2020-0037. Epub 2020 Jul 20.Immunotherapy. 2020. PMID: 32684057 
  6. Absence of cGAS-mediated type I IFN responses in HIV-1-infected T cells. Elsner C, Ponnurangam A, Kazmierski J, Zillinger T, Jansen J, Todt D, Döhner K, Xu S, Ducroux A, Kriedemann N, Malassa A, Larsen PK, Hartmann G, Barchet W, Steinmann E, Kalinke U, Sodeik B, Goffinet C.Elsner C, et al. Among authors: Hartmann G. Proc Natl Acad Sci U S A. 2020 Aug 11;117(32):19475-19486. doi: 10.1073/pnas.2002481117. Epub 2020 Jul 24.Proc Natl Acad Sci U S A. 2020. PMID: 32709741
  7. Emergence of a High-Plasticity Cell State during Lung Cancer Evolution. Marjanovic ND, Hofree M, Chan JE, Canner D, Wu K, Trakala M, Hartmann G, Smith OC, Kim JY, Evans KV, Hudson A, Ashenberg O, Porter CBM, Bejnood A, Subramanian A, Pitter K, Yan Y, Delorey T, Phillips DR, Shah N, Chaudhary O, Tsankov A, Hollmann T, Rekhtman N, Massion PP, Poirier JT, Mazutis L, Li R, Lee JH, Amon A, Rudin CM, Jacks T, Regev A, Tammela T.Marjanovic ND, et al. Among authors: Hartmann G. Cancer Cell. 2020 Aug 10;38(2):229-246.e13. doi: 10.1016/j.ccell.2020.06.012. Epub 2020 Jul 23.Cancer Cell. 2020. PMID: 
  8. Zuo1 supports G4 structure formation and directs repair toward nucleotide excision repair.De Magis A, Götz S, Hajikazemi M, Fekete-Szücs E, Caterino M, Juranek S, Paeschke K.
    Nat Commun. 2020 Aug 6;11(1):3907.
  9. Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy. Such L, Zhao F, Liu D, Thier B, Le-Trilling VTK, Sucker A, Coch C, Pieper N, Howe S, Bhat H, Kalkavan H, Ritter C, Brinkhaus R, Ugurel S, Köster J, Seifert U, Dittmer U, Schuler M, Lang KS, Kufer TA, Hartmann G, Becker JC, Horn S, Ferrone S, Liu D, Van Allen EM, Schadendorf D, Griewank K, Trilling M, Paschen A.Such L, et al. Among authors: Hartmann G. J Clin Invest. 2020 Aug 3;130(8):4266-4281. doi: 10.1172/JCI131572.J Clin Invest. 2020. PMID: 32427578 Free article. 
  10. Antitumor immunity and T-cell avidity. Brossart P. Blood. 2020 Jul 23;136(4):378-380. doi: 10.1182/blood.2020006562.Blood. 2020. PMID: 32702125 No abstract available. 
  11. Treatment Response Monitoring in Patients with Advanced Malignancies Using Cell-Free SHOX2 and SEPT9 DNA Methylation in Blood: An Observational Prospective Study. de Vos L, Jung M, Koerber RM, Bawden EG, Holderried TAW, Dietrich J, Bootz F, Brossart P, Kristiansen G, Dietrich D.de Vos L, et al. Among authors: Brossart P. J Mol Diagn. 2020 Jul;22(7):920-933. doi: 10.1016/j.jmoldx.2020.04.205. Epub 2020 Apr 30.J Mol Diagn. 2020. PMID: 
  12. Immune Sensing Mechanisms that Discriminate Self from Altered Self and Foreign Nucleic Acids. Bartok E, Hartmann G.Bartok E, et al. . Immunity. 2020 Jul 14;53(1):54-77. doi: 10.1016/j.immuni.2020.06.014.Immunity. 2020. PMID: 32668228 Free PMC article. Review. 
  13. Selective BET-bromodomain inhibition by JQ1 suppresses dendritic cell maturation and antigen-specific T-cell responses. Remke N, Bisht S, Oberbeck S, Nolting J, Brossart P.Remke N, et al. Among authors: brossart p. Cancer Immunol Immunother. 2020 Jul 10. doi: 10.1007/s00262-020-02665-x. Online ahead of print.Cancer Immunol Immunother. 2020. PMID: 32651619 
  14. Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma. Hoffmann F, Zarbl R, Niebel D, Sirokay J, Fröhlich A, Posch C, Holderried TAW, Brossart P, Saavedra G, Kuster P, Strieth S, Gielen GH, Ring SS, Dietrich J, Pietsch T, Flatz L, Kristiansen G, Landsberg J, Dietrich D.Hoffmann F, et al. Among authors: brossart p. Clin Epigenetics. 2020 Jun 26;12(1):94. doi: 10.1186/s13148-020-00883-9.Clin Epigenetics. 2020. PMID: 32586358 Free PMC article. 
  15. Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire. Haen SP, Löffler MW, Rammensee HG, Brossart P.Haen SP, et al. Among authors: brossart p. Nat Rev Clin Oncol. 2020 Jun 22:1-16. doi: 10.1038/s41571-020-0387-x. Online ahead of print.Nat Rev Clin Oncol. 2020. PMID: 32572208 Free PMC article. Review.
  16. Long-term follow-up of Cladribine, high-dose Cytarabine, and Idarubicin as salvage treatment for relapsed acute myeloid leukemia and literature review. Mayer K, Hahn-Ast C, Schwab K, Schmidt-Wolf IGH, Brossart P, Glasmacher A, von Lilienfeld-Toal M.Mayer K, et al. Eur J Haematol. 2020 Jun;104(6):538-545. doi: 10.1111/ejh.13395. Epub 2020 Mar 10.Eur J Haematol. 2020. PMID: 32049382 
  17. Lipid-Droplet Formation Drives Pathogenic Group 2 Innate Lymphoid Cells in Airway Inflammation. Karagiannis F, Masouleh SK, Wunderling K, Surendar J, Schmitt V, Kazakov A, Michla M, Hölzel M, Thiele C, Wilhelm C.Karagiannis F, et al. Among authors: holzel m. Immunity. 2020 May 19;52(5):885. doi: 10.1016/j.immuni.2020.04.021.Immunity. 2020. PMID: 32433951 No abstract available.
  18. Health literacy, mental disorders and fear of progression and their association with a need for psycho-oncological care over the course of a breast cancer treatment. Nakata H, Halbach S, Geiser F, Stock S, Kowalski C, Enders A, Pfaff H, Ernstmann N.Psychol Health Med. 2020 Jun 2:1-14. doi: 10.1080/13548506.2020.1772987. Online ahead of print.PMID: 32484756 
  19. The key role of palliative care in response to the COVID-19 tsunami of suffering. Radbruch L, Knaul FM, de Lima L, de Joncheere C, Bhadelia A.Lancet. 2020 May 9;395(10235):1467-1469. doi: 10.1016/S0140-6736(20)30964-8. Epub 2020 Apr 22.
  20. The role of antigen-spreading in the efficacy of immunotherapies. Brossart P. Clin Cancer Res. 2020 May 1:clincanres.0305.2020. doi: 10.1158/1078-0432.CCR-20-0305. Online ahead of print.Clin Cancer Res. 2020. PMID: 32357962 
  21. The landscape of CD28, CD80, CD86, CTLA4, and ICOS DNA methylation in head and neck squamous cell carcinomas. de Vos L, Grünwald I, Bawden EG, Dietrich J, Scheckenbach K, Wiek C, Zarbl R, Bootz F, Landsberg J, Dietrich D.de Vos L, et al. Among authors: Dietrich D. Epigenetics. 2020 Apr 21:1-18. doi: 10.1080/15592294.2020.1754675. Online ahead of print.Epigenetics. 2020. PMID:  
  22. Immune Sensing of Synthetic, Bacterial, and Protozoan RNA by Toll-like Receptor 8 Requires Coordinated Processing by RNase T2 and RNase 2. Ostendorf T, Zillinger T, Andryka K, Schlee-Guimaraes TM, Schmitz S, Marx S, Bayrak K, Linke R, Salgert S, Wegner J, Grasser T, Bauersachs S, Soltesz L, Hübner MP, Nastaly M, Coch C, Kettwig M, Roehl I, Henneke M, Hoerauf A, Barchet W, Gärtner J, Schlee M, Hartmann G, Bartok E.Ostendorf T, et al. Among authors: Hartmann G. Immunity. 2020 Apr 14;52(4):591-605.e6. doi: 10.1016/j.immuni.2020.03.009.Immunity. 2020. PMID: 32294405 
  23. Lipid-Droplet Formation Drives Pathogenic Group 2 Innate Lymphoid Cells in Airway Inflammation. Karagiannis F, Masouleh SK, Wunderling K, Surendar J, Schmitt V, Kazakov A, Michla M, Hölzel M, Thiele C, Wilhelm C.Karagiannis F, et al. Among authors: holzel m. Immunity. 2020 Apr 14;52(4):620-634.e6. doi: 10.1016/j.immuni.2020.03.003. Epub 2020 Apr 7.Immunity. 2020. 
  24. High RIG-I expression in ovarian cancer associates with an immune-escape signature and poor clinical outcome. Wolf D, Fiegl H, Zeimet AG, Wieser V, Marth C, Sprung S, Sopper S, Hartmann G, Reimer D, Boesch M.Wolf D, et al. Among authors: Hartmann G. Int J Cancer. 2020 Apr 1;146(7):2007-2018. doi: 10.1002/ijc.32818. Epub 2019 Dec 19.
  25. Prostate-specific Membrane Antigen Imaging: A Game Changer in Prostate Cancer Diagnosis and Therapy Planning. Ahmadzadehfar H, Essler M.Eur Urol. 2020 Apr;77(4):418-419. doi: 10.1016/j.eururo.2019.02.028. Epub 2019 Mar 2.
  26. A high-salt diet compromises antibacterial neutrophil responses through hormonal perturbation. Jobin K, Stumpf NE, Schwab S, Eichler M, Neubert P, Rauh M, Adamowski M, Babyak O, Hinze D, Sivalingam S, Weisheit C, Hochheiser K, Schmidt SV, Meissner M, Garbi N, Abdullah Z, Wenzel U, Hölzel M, Jantsch J, Kurts C.Jobin K, et al. Among authors: holzel m. Sci Transl Med. 2020 Mar 25;12(536):eaay3850. doi:
  27. LAG3 (LAG-3, CD223) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma. Klümper N, Ralser DJ, Bawden EG, Landsberg J, Zarbl R, Kristiansen G, Toma M, Ritter M, Hölzel M, Ellinger J, Dietrich D.Klümper N, et al. Among authors: holzel m. J Immunother Cancer. 2020 Mar;8(1):e000552. doi: 10.1136/jitc-2020-000552.J Immunother Cancer. 2020. PMID: 32234847 Free PMC article. 
  28. Complex human adenoid tissue-based ex vivo culture systems reveal anti-inflammatory drug effects on germinal center T and B cells.Schmidt A, Huber JE, Sercan Alp Ö, Gürkov R, Reichel CA, Herrmann M, Keppler OT, Leeuw T, Baumjohann D.EBioMedicine. 2020 Mar;53:102684. doi: 10.1016/j.ebiom.2020.102684. Epub 2020 Feb 27.
  29. Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study. Ström P, Kartasalo K, Olsson H, Solorzano L, Delahunt B, Berney DM, Bostwick DG, Evans AJ, Grignon DJ, Humphrey PA, Iczkowski KA, Kench JG, Kristiansen G, van der Kwast TH, Leite KRM, McKenney JK, Oxley J, Pan CC, Samaratunga H, Srigley JR, Takahashi H, Tsuzuki T, Varma M, Zhou M, Lindberg J, Lindskog C, Ruusuvuori P, Wählby C, Grönberg H, Rantalainen M, Egevad L, Eklund M. Lancet Oncol. 2020 Feb;21(2):222-232. doi: 10.1016/S1470-2045(19)30738-7. Epub 2020 Jan 8.
  30. The role of environmental stress and DNA methylation in the longitudinal course of bipolar disorder. Comes AL, Czamara D, Adorjan K, Anderson-Schmidt H, Andlauer TFM, Budde M, Gade K, Hake M, Kalman JL, Papiol S, Reich-Erkelenz D, Klöhn-Saghatolislam F, Schaupp SK, Schulte EC, Senner F, Juckel G, Schmauß M, Zimmermann J, Reimer J, Reininghaus E, Anghelescu IG, Konrad C, Thiel A, Figge C, von Hagen M, Koller M, Dietrich DE, Stierl S, Scherk H, Witt SH, Sivalingam S, Degenhardt F, Forstner AJ, Rietschel M, Nöthen MM, Wiltfang J, Falkai P, Schulze TG, Heilbronner U.Comes AL, et al. Int J Bipolar Disord. 2020 Feb 12;8(1):9. doi: 10.1186/s40345-019-0176-6.Int J Bipolar Disord. 2020. PMID: 32048126 Free PMC article. 
  31. H3K27me3 and EZH2 expression in melanoma: relevance for melanoma progression and response to immune checkpoint blockade. Hoffmann F, Niebel D, Aymans P, Ferring-Schmitt S, Dietrich D, Landsberg J. Hoffmann F, et al. Clin Epigenetics. 2020 Feb 10;12(1):24. doi: 10.1186/s13148-020-0818-7.Clin Epigenetics. 2020. PMID: 32041674 Free PMC article. 
  32. Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma. Fröhlich A, Loick S, Bawden EG, Fietz S, Dietrich J, Diekmann E, Saavedra G, Fröhlich H, Niebel D, Sirokay J, Zarbl R, Gielen GH, Kristiansen G, Bootz F, Landsberg J, Dietrich D.Fröhlich A, et al. EBioMedicine. 2020 Feb;52:102647. doi: 10.1016/j.ebiom.2020.102647. Epub 2020 Feb 3.EBioMedicine. 2020. PMID: 32028068 Free PMC article. 
  33. Systemic Therapy of Neuroendocrine Neoplasia: Single Center Experience from a Cohort of 110 Consecutive Cases. Mayer K, Kiry S, Yordanova A, Ahmadzadehfar H, Gaertner FC, Bundschuh RA, Essler M, Gonzalez-Carmona MA, Strassburg CP, Matthaei H, Lingohr P, Bisht S, Brossart P, Feldmann G.Mayer K, et al. Among authors: Brossart P. Int J Endocrinol. 2020 Jan 31;2020:1491475. doi: 

 

2019

  1. EANO-EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma. Franceschi E, Hofer S, Brandes AA, Frappaz D, Kortmann RD, Bromberg J, Dangouloff-Ros V, Boddaert N, Hattingen E, Wiestler B, Clifford SC, Figarella-Branger D, Giangaspero F, Haberler C, Pietsch T, Pajtler KW, Pfister SM, Guzman R, Stummer W, Combs SE, Seidel C, Beier D, McCabe MG, Grotzer M, Laigle-Donadey F, Stücklin ASG, Idbaih A, Preusser M, van den Bent M, Weller M, Hau P. Lancet Oncol. 2019 Dec;20(12):e715-e728. doi: 10.1016/S1470-2045(19)30669-2. PMID: 31797797.
  2. Electronic Decay of Singly Charged Ground-State Ions by Charge Transfer via van der Waals Bonds. Hans A, Miteva T, Holzapfel X, Ozga C, Schmidt P, Otto H, Hartmann G, Richter C, Sisourat N, Ehresmann A, Gokhberg K, Hergenhahn U, Knie A.Hans A, et al. Among authors: Hartmann G. Phys Rev Lett. 2019 Nov 22;123(21):213001. doi: 10.1103/PhysRevLett.123.213001.Phys Rev Lett. 2019. PMID: 31809166 
  3. Molecular and immune correlates of TIM-3 (HAVCR2) and galectin 9 (LGALS9) mRNA expression and DNA methylation in melanoma. Holderried TAW, de Vos L, Bawden EG, Vogt TJ, Dietrich J, Zarbl R, Bootz F, Kristiansen G, Brossart P, Landsberg J, Dietrich D.Holderried TAW, et al. Clin Epigenetics. 2019 Nov 20;11(1):161. doi: 10.1186/s13148-019-0752-8.Clin Epigenetics. 2019. PMID: 31747929 Free PMC 
  4. DNA methylation of indoleamine 2,3-dioxygenase 1 (IDO1) in head and neck squamous cell carcinomas correlates with IDO1 expression, HPV status, patients' survival, immune cell infiltrates, mutational load, and interferon γ signature. Sailer V, Sailer U, Bawden EG, Zarbl R, Wiek C, Vogt TJ, Dietrich J, Loick S, Grünwald I, Toma M, Golletz C, Gerstner A, Kristiansen G, Bootz F, Scheckenbach K, Landsberg J, Dietrich D.Sailer V, et al. EBioMedicine. 2019 Oct;48:341-352. doi: 10.1016/j.ebiom.2019.09.038
  5. RIG-I activation is critical for responsiveness to checkpoint blockade. Heidegger S et al. Sei lmmunol. 2019; 4(39) pii: eaau8943.
  6. Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial. Weller J, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Hau P, Krex D, Grauer O, Goldbrunner R, Bähr O, Uhl M, Seidel C, Tabatabai G, Brehmer S, Bullinger L, Galldiks N, Schaub C, Kebir S, Stummer W, Simon M, Fimmers R, Coch C, Glas M, Herrlinger U, Schäfer N. Lancet Oncol. 2019 Oct;20(10):1444-1453. doi: 10.1016/S1470-2045(19)30502-9. Epub 2019 Sep. 2.
  7. The Rad51 paralogs facilitate a novel DNA strand specific damage tolerance pathway. Rosenbaum JC, Bonilla B, Hengel SR, Mertz TM, Herken BW, Kazemier HG, Pressimone CA, Ratterman TC, MacNary E, De Magis A, Kwon Y, Godin SK, Van Houten B, Normolle DP, Sung P, Das SR, Paeschke K, Roberts SA, VanDemark AP, Bernstein KA. Nat Commun. 2019 Aug 5;10(1):3515. doi: 10.1038/s41467-019-11374-8.
  8. DHX36 prevents the accumulation of translationally inactive mRNAs with G4-structures in untranslated regions. Sauer M, Juranek SA, Marks J, De Magis A, Kazemier HG, Hilbig D, Benhalevy D, Wang X, Hafner M, Paeschke K. Nat Commun. 2019 Jun 3;10(1):2421.
  9. SIOP-E-BTG and GPOH Guidelines for Diagnosis and Treatment of Children and Adolescents with Low Grade Glioma. Gnekow AK, Kandels D, Tilburg CV, Azizi AA, Opocher E, Stokland T, Driever PH, Schouten-van Meeteren AYN, Thomale UW, Schuhmann MU, Czech T, Goodden JR, Warmuth-Metz M, Bison B, Avula S, Kortmann RD, Timmermann B, Pietsch T, Witt O.. Klin Padiatr. 2019 May;231(3):107-135. English. doi: 10.1055/a-0889-8256. Epub 2019 May 20
  10. A Novel G-Quadruplex Binding Protein in Yeast-Slx9. Molecules. Götz S, Pandey S, Bartsch S, Juranek S, Paeschke K. 2019 May 7;24(9):pii: E1774. doi: 10.3390/molecules24091774.
  11. EF24 Suppresses Cholangiocellular Carcinoma Progression, lnhibits STAT3 Phosphorylation, and lnduces Apoptosis via ROS-Mediated Oxidative Stress. Bisht S, Nolting J, Wenzel J, Brossart P, Feldmann G. J Oncol. 2019 Mar 4;2019:8701824. doi: 10.1155/2019/8701824.

2018

  1. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial. Goschzik T, Schwalbe EC, Hicks D, Smith A, Zur Muehlen A, Figarella-Branger D, Doz F, Rutkowski S, Lannering B, Pietsch T, Clifford SC. Lancet Oncol. 2018 Dec;19(12):1602-1616. doi: 10.1016/S1470-2045(18)30532-1.
  2. Macrophage-Derived Neuropilin-2 Exhibits Novel Tumor-Promoting Functions. Roy S, Bag AK, Dutta S, Polavaram NS, Islam R, Schellenburg S, Banwait J, Guda C, Ran S, Hollingsworth MA, Singh RK, Talmadge JE, Muders MH*, Batra SK, Datta K.* Cancer Res. 2018 Oct 1;78(19):5600-5617. doi: 10.1158/0008-5472.CAN-18-0562. Epub 2018 Aug 15. *Gemeinsame Letzt- und Korrespondenzautoren.

2017

  1. Type I interferon-mediated autoinflammation due to DNase II deficiency. Rodero M P, Tesser A, Bartok E, Rice G I, Della Mina E, Depp M, Beitz B, Bondet V, Cagnard N, Duffy D, Dussiot M, Frémond M-L, Gattorno M, Guillem F, Kitabayashi N, Porcheray F,  Rieux-Laucat F, Seabra L, Uggenti C, Volpi S, Zeef L A H, Alyanakian M-A, Beltrand J, Bianco A M, Boddaert N, Brouzes C, Candon S, Caorsi R, Charbit M, Fabre M, Faletra F, Girard M, Harroche A, Hartmann E, Lasne D, Marcuzzi A, Neven B, Nitschke P, Pascreau T, Pastore S, Picard C, Picco P, Piscianz E, Polak M, Quartier P, Rabant M, Stocco G, Taddio A, Uettwiller F, Valencic E, Vozzi D, Hartmann G, Barchet W, Hermine O, Bader-Meunier B, Tommasini A, Crow Y J. Nat Commun. 2017 Dec 19;8(1):2176. doi: 10.1038/s41467-017-01932-3.
  2. Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy. Glodde N, Bald T, van den Boorn-Konijnenberg D, Nakamura K, O'Donnell J, Szczepanski S, Brandes M, Eickhoff S, Das I, Shridhar N, Hinze D, Rogava M, van der Sluis T, Ruotsalainen J, Gaffal E, Landsberg J, Ludwig K, Wilhelm C, Riek-Burchardt M, Müller A, Gebhardt C, Scolyer R, Long G, Janzen V, Teng M, Kastenmüller W, Mazzone M, Smyth M, Tüting T, Hölzel M.Immunity. 2017 Oct 17;47(4):789-802.e9. doi: 10.1016/j.immuni.2017.09.012.
  3. The epidermal polarity protein Par3 is a non-cell autonomous suppressor of malignant melanoma. Mescher M, Jeong P, Knapp S, Rübsam M, Saynisch M, Kranen M, Landsberg J, Schlaak M, Mauch C, Tüting T, Niessen C, Iden S.J Exp Med. 2017 Feb;214(2):339-358. doi: 10.1084/jem.20160596. Epub 2017 Jan 17.
  4. MAPK Signaling and lnflammation Link Melanoma Phenotype Switching to lnduction of CD73 during lmmunotherapy. Reinhardt J, Landsberg J, Schmid-Burgk JL, Ramis BB, Bald T, Glodde N, Lopez-Ramos D, Young A, Ngiow SF, Nettersheim D, Schorle H, Quast T, Kolanus W, Schadendorf D, Long GV, Madore J, Scolyer RA, Ribas A, Smyth MJ, Tumeh PC, Tüting T, Hölzel M. Cance_rRes. 2017 Sep 1;77(17):4697-4709. doi: 10.1158/0008-5472.CAN-17-0395. Epub 2017 Jun 26.
  5. Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia. Sopper S, Mustjoki S, White D, Hughes T, Valent P, Burchert A, Gjertsen BT, Gastl G, Baldauf M, Trajanoski Z, Giles F, Hochhaus A, Ernst T, Schenk T, Janssen JJ, Ossenkoppele GJ, Porkka K, Wolf D. J Clin Oncol. 2017 Jan 10;35(2):175-184.

2016

  1. Update on the integrated histopathological and genetic classification of medulloblastoma - a practical diagnostic guideline. Pietsch T, Haberler C.. Clin Neuropathol. 2016 Nov/Dec;35(6):344-352. doi: 10.5414/NP300999. PMID: 27781424; PMCID: PMC5094373.
  2. Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases. Kebir S, Rauschenbach L, Galldiks N, Schlaak M, Hattingen E, Landsberg J, Bundschuh R, Langen K, Scheffler B, Herrlinger U, Glas M. Neuro Oncol. 2016 Oct;18(10):1462-4. doi: 10.1093/neuonc/now154. Epub 2016 Sep 2.
  3. Treatment of Children and Adolescents With Metastatic Medulloblastoma and Prognostic Relevance of Clinical and Biologic Parameters. von Bueren AO, Kortmann RD, von Hoff K, Friedrich C, Mynarek M, Müller K, Goschzik T, Zur Mühlen A, Gerber N, Warmuth-Metz M, Soerensen N, Deinlein F, Benesch M, Zwiener I, Kwiecien R, Faldum A, Bode U, Fleischhack G, Hovestadt V, Kool M, Jones D, Northcott P, Kuehl J, Pfister S, Pietsch T, Rutkowski S. J Clin Oncol. 2016 Dec;34(34):4151-4160. Epub 2016 Oct 31.
  4. Discriminating self from non-self in nucleic acid sensing. Schlee M, Hartmann G. Nat Rev Immunol. 2016 Sep;16(9):566-80. doi: 10.1038/nri.2016.78.
  5. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Packer R, Rutkowski S, Pfister SM, Taylor MD, Pomeroy SL.. Acta Neuropathol. 2016 Jun;131(6):821-31. doi: 10.1007/s00401-016-1569-6. Epub 2016 Apr 4. PMID: 27040285; PMCID: PMC4867119.
  6. Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. Herrlinger U, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch MW, Uhl M, Maciaczyk J, Grau S, Schnell O, Hänel M, Krex D, Vajkoczy P, Gerlach R, Kortmann RD, Mehdorn M, Tüttenberg J, Mayer-Steinacker R, Fietkau R, Brehmer S, Mack F, Stuplich M, Kebir S, Kohnen R, Dunkl E, Leutgeb B, Proescholdt M, Pietsch T, Urbach H, Belka C, Stummer W, Glas M. J Clin Oncol 2016 Mar [Epub ahead of print]
  7. Cutting Edge: The RIG-I Ligand 3pRNA Potently Improves CTL Cross-Priming and Facilitates Antiviral Vaccination. Hochheiser K, Klein M, Gottschalk C, Hoss F, Scheu S, Coch C, Hartmann G, Kurts C. J Immunol. 2016 Mar 15;196(6):2439-43. doi: 10.4049/jimmunol.1501958. Epub 2016 Jan 27.
  8. New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Sturm D, Orr BA, Toprak UH, Hovestadt V, Jones DTW, Capper D, Sill M, Buchhalter I, Northcott PA, Leis I, Ryzhova M, Koelsche C, Pfaff E, Allen SJ, Balasubramanian G, Worst BC, Pajtler KW, Brabetz S, Johann PD, Sahm F, Reimand J, Mackay A, Carvalho DM, Remke M, Phillips JJ, Perry A, Cowdrey C, Drissi R, Fouladi M, Giangaspero F, Łastowska M, Grajkowska W, Scheurlen W, Pietsch T, Hagel C, Gojo J, Lötsch D, Berger W, Slavc I, Haberler C, Jouvet A, Holm S, Hofer S, Prinz M, Keohane C, Fried I, Mawrin C, Scheie D, Mobley BC, Schniederjan MJ, Santi M, Buccoliero AM, Dahiya S, Kramm CM, von Bueren AO, von Hoff K, Rutkowski S, Herold-Mende C, Frühwald MC, Milde T, Hasselblatt M, Wesseling P, Rößler J, Schüller U, Ebinger M, Schittenhelm J, Frank S, Grobholz R, Vajtai I, Hans V, Schneppenheim R, Zitterbart K, Collins VP, Aronica E, Varlet P, Puget S, Dufour C, Grill J, Figarella-Branger D, Wolter M, Schuhmann MU, Shalaby T, Grotzer M, van Meter T, Monoranu CM, Felsberg J, Reifenberger G, Snuderl M, Forrester LA, Koster J, Versteeg R, Volckmann R, van Sluis P, Wolf S, Mikkelsen T, Gajjar A, Aldape K, Moore AS, Taylor MD, Jones C, Jabado N, Karajannis MA, Eils R, Schlesner M, Lichter P, von Deimling A, Pfister SM, Ellison DW, Korshunov A, Kool M. Cell. 2016 Feb 25;164(5):1060-1072. doi: 10.1016/j.cell.2016.01.015.
  9. A Preclinical Model of Malignant Peripheral Nerve Sheath Tumor-like Melanoma Is Characterized by lnfiltrating Mast Cells. Hölzel M, Landsberg J, Glodde N, Bald T, Rogava M, Riesenberg S, Becker A, Jönsson G, Tüting T. Cancer_Res. 2016 Jan 15;76(2):251-63. doi: 10.1158/0008-5472.CAN-15-1090.

2015

  1. MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment. Riesenberg S, Groetchen A, Siddaway R, Bald T, Reinhardt J , Smorra D, Kohlmeyer J, Renn M, Phung B, Aymans P, Schmidt T, Hornung V, Davidson I, Goding CR, Jönsson G, Landsberg J, Tüting T, Hölzel M. Nat Cornmun. 2015 Nov 4;6:8755. doi: 10.1038/ncomms9755.

2014

  1. International Society Of Neuropathology--Haarlem. International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading. Louis DN, Perry A, Burger P, Ellison DW, Reifenberger G, von Deimling A, Aldape K, Brat D, Collins VP, Eberhart C, Figarella-Branger D, Fuller GN, Giangaspero F, Giannini C, Hawkins C, Kleihues P, Korshunov A, Kros JM, Beatriz Lopes M, Ng HK, Ohgaki H, Paulus W, Pietsch T, Rosenblum M, Rushing E, Soylemezoglu F, Wiestler O, Wesseling P;. Brain Pathol. 2014 Sep;24(5):429-35. doi: 10.1111/bpa.12171. Epub 2014
  2. Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation. Bald T, Landsberg J, Lopez-Ramos D, Renn M, Glodde N, Jansen P, Gaffal E, Steitz J, Tolba R, Kalinke U, Limmer A, Jönsson G, Hölzel M, Tüting T. Cancer Discov. 2014 Jun;4(6):674-87. doi: 10.1158/2159-8290.CD-13-0458. Epub 2014 Mar 3.
  3. Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma. Bald T, Quast T, Landsberg J, Rogava M, Glodde N, Lopez-Ramos D, Kohlmeyer J, Riesenberg S, van den Boorn-Konijnenberg D, Hömig­-Hölzel C, Reuten R, Schadow B, Weighardt H, Wenzel D, Helfrich I, Schadendorf D, Bloch W, Bianchi ME, Lugassy C, Barnhill RL, Koch M, Fleischmann BK, Förster I, Kastenmüller W, Kolanus W, Hölzel M, Gaffal E, Tüting T. Nature. 2014 Mar 6;507(7490):109-13. doi: 10.1038/nature13111. Epub 2014 Feb 26.

2013

  1. cGAS produces a 2'-5'-linked cyclic dinucleotide second messenger that activates STING. Ablasser A, Goldeck M, Cavlar T, Deimling T, Witte G, Röhl I, Hopfner KP, Ludwig J, Hornung V. Nature 2013; 498(7454):380-4.
  2. Cell intrinsic immunity spreads to bystander cells via the intercellular transfer of cGAMP. Ablasser A, Schmid-Burgk JL, Hemmerling I, Horvath GL, Schmidt T, Latz E, Hornung V. Nature 2013; 503(7477):530-4.
  3. Oxidative damage of DNA confers resistance to cytosolic nuclease TREX1 degradation and potentiates STING-dependent immune sensing. Gehrke N, Mertens C, Zillinger T, Wenzel J, Bald T, Zahn S, Tüting T, Hartmann G, Barchet W. Immunity 2013; 39(3):482-95
  4. Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? Hölzel M, Bovier A, Tüting T. Nat Rev Cancer 2013; 13(5):365-76
  5. Vemurafenib for leptomeningeal melanomatosis. Schäfer N, Scheffler B, Stuplich M, Schaub C, Kebir S, Rehkämper C, Mack F, Niehusmann P, Simon M, Greschus S, Kuchelmeister K, Herrlinger U, Glas M. J Clin Oncol. 2013 Apr 10;31(11):e173-4.

2012

  1. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Landsberg J, Kohlmeyer J, Renn M, Bald T, Rogava M, Cron M, Fatho M, Lennerz V, Wölfel T, Hölzel M, Tüting T. Nature. 2012 Oct 18;490(7420):412-6. doi: 10.1038/nature11538. Epub 2012 Oct 10.

2011

2010

  1. Alternative cross-priming through CCL17-CCR4-mediated attraction of CTLs toward NKT cell-licensed DCs. Semmling V, Lukacs-Kornek V, Thaiss CA, Quast T, Hochheiser K, Panzer U, Rossjohn J, Perlmutter P, Cao J, Godfrey DI, Savage PB, Knolle PA, Kolanus W, Förster I, Kurts C. Nat Immunol. 2010; 11(4):313-20

2009

  1. Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy. Kohlmeyer J, Cron M, Landsberg J, Bald T, Renn M, Mikus S, Bondong S, Wikasari D, Gaffal E, Hartmann G, Tüting T. Cancer Res. 2009 Aug 1;69(15):6265-74. doi: 10.1158/0008-5472.CAN-09-0579. Epub 2009 Jul 21.
  2. Long-term survival of glioblastoma patients treated with radiotherapy and lomustine plus temozolomide. Glas M, Happold C, Rieger J, Wiewrodt D, Bähr O, Steinbach JP, Wick W, Kortmann RD, Reifenberger G, Weller M, Herrlinger U. J Clin Oncol. 2009 Mar 10;27(8):1257-61. doi: 10.1200/JCO.2008.19.2195. Epub 2009 Feb 2.
Roy S, Bag AK, Dutta S, Polavaram NS, Islam R, Schellenburg S, Banwait J, Guda C, Ran S, Hollingsworth MA, Singh RK, Talmadge JE, Muders MH*, Batra SK, Datta K.*

2008

  1. 5'-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Poeck H, Besch R, Maihoefer C, Renn M, Tormo D, Shulga Morskaya S, Kirschnek S, Gaffal E, Landsberg J, Hellmuth J, Schmidt A, Anz D, Bscheider M, Schwerd T, Berking C, Bourquin C, Kalinke U, Kremmer E, Kato H, Akira S, Meyers R, Häcker G, Neuenhahn M, Busch D, Ruland J, Rothenfusser S, Prinz M, Hornung V, Endres S, Tüting T, Hartmann G. Nat Med. 2008 Nov;14(11):1256-63. doi: 10.1038/nm.1887. Epub 2008 Nov 2.

Das CIO Bonn ist Teil des Krebszentrums CIO Aachen Bonn Köln Düsseldorf.
Lesen Sie mehr darüber auf der gemeinsamen Webseite des Centrums für Integrierte Onkologie Aachen Bonn Köln Düsseldorf.

© 2024 CIO Bonn